Entities › name
167 headlines · 15 outlets · 2026-10-19 → 2026-11-14 · Wikipedia ↗ · 🔒 Follow
TORONTO and BARBADOS, Nov. 13, 2026 /CNW/ -- Sagicor Financial Company Ltd. (TSX: SFC) ("Sagicor Financial" or "Sagicor" or the "Company") today issued a correction to the dividend payment date stated in the version of its news release titled "Sagicor Financial Reports Third Quarter 2026...
BOISE, Idaho, Nov. 13, 2026 /PRNewswire/ -- Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") announced the filing of its unaudited condensed consolidated financial results for the period ended September 30, 2026. For details, please...
BOISE, Idaho, Nov. 13, 2026 /CNW/ -- Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") announced the filing of its unaudited condensed consolidated financial results for the period ended September 30, 2026. For details, please see...
VANCOUVER, BC and GLIL YAM, Israel, Nov. 13, 2026 /PRNewswire/ -- IM Cannabis Corp. (the "Company") (NASDAQ: IMCC) announced its financial results for the third quarter and first nine months ended September 30, 2026. For the third quarter of 2026, revenue totaled C$1.65 million, compared...
Revenue for the First Nine Months of 2026 Surged 382.1% Year-on-Year to Approximately $9.6 Million Profit Turnaround for the First Nine Months of 2026 with Net Income of $3.6 Million OSAKA, Japan, Nov. 13, 2026 /PRNewswire/ -- FiEE, Inc. (NASDAQ:FIEE) ("FiEE," the "Company," "we," "our,"...
SAN DIEGO, Nov. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Upcoming Clinical Milestones Ozekibart...
Colombia's state oil company reported third-quarter net income of about US$1.45 billion, up 86%, driven by higher oil and refining prices. The post Ecopetrol Profit Jumps 86% in Third Quarter appeared first on The Rio Times .
Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of Clinical Development for DA-1726 and Vanoglipel Full Data From the Phase 1 Parts 3A and 3B...
ATHENS, Greece, Nov. 13, 2026 /PRNewswire/ -- Danaos Corporation (NYSE: DAC), one of the world's largest independent owners of containerships, announced today that it will release its results for the third quarter ended September 30, 2026, after the close of the market in New York on...
Lucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwide Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission PAVmed engaged with FDA on PortIO and Octeris Conference call and webcast...
